# Beyond Air to Participate in the D. Boral Capital Global Conference 2026
Canonical URL: https://biopharmsignal.com/news/XAIR/beyond-air-to-participate-in-the-d-boral-capital-global-conference-2026-cf820619
Ticker: XAIR
Company: Beyond Air
Source: Beyond Air
Published: 2026-04-15 12:00 EST
## Summary

Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company...

## Article Body
Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients’ lives, today announced that Robert Goodman, Chief Executive Officer, and Dan Moorhead, Chief Financial Officer of Beyond Air, will participate in the D. Boral Capital Global Conference 2026, which is being held on Thursday, May 7 th , at The Plaza Hotel in New York.

| Conference |  |  |
| --- | --- | --- |
| Format: |  | One-on-one meetings |
| Conference Dates: |  | May 7th |
| Participants: |  | Robert Goodman, CEO, and Dan Moorhead, CFO of Beyond Air |

If you are interested in requesting a one-on-one meeting at the conference, please contact your D. Boral Capital representative to schedule accordingly.

About Beyond Air, Inc.

Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net .

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the Company’s expectations related to the commercial growth, market adoption of LungFit PH, expansion in the U.S. and international markets, and the Company’s long-term strategic and financial performance. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “potential,” “will,” “would,” “could,” “may,” and similar expressions, or by the use of future tense. These statements are based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management.

Because forward-looking statements relate to future events, they are subject to inherent risks and uncertainties, many of which are beyond the Company’s control, that could cause actual results to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s ability to successfully execute its commercial strategy, achieve market adoption of its products, maintain and expand customer relationships, manage leadership transitions effectively, obtain additional financing, and other risks described in the “Risk Factors” section of Beyond Air, Inc.’s most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission.

CONTACTS:

Investor Relations contact

Corey Davis, Ph.D. LifeSci Advisors, LLC cdavis@lifesciadvisors.com (212) 915-2577
## Recent Company News
- 2026-06-26 11:00 EST — [Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/XAIR/beyond-air-reports-fourth-quarter-and-full-year-2026-financial-results-and-provi-8c4a9c6f) — Source: Beyond Air
- 2026-06-22 20:01 EST — [Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast](https://biopharmsignal.com/news/XAIR/beyond-air-schedules-fiscal-year-end-2026-financial-results-conference-call-and--03178c17) — Source: Beyond Air
- 2026-06-10 12:00 EST — [Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting](https://biopharmsignal.com/news/XAIR/beyond-air-inc-urges-stockholders-to-vote-for-all-proposals-ahead-of-the-upcomin-31020f6e) — Source: Beyond Air
- 2026-06-01 12:00 EST — [Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing](https://biopharmsignal.com/news/XAIR/beyond-air-receives-nasdaq-hearing-panel-decision-granting-continued-listing-fe2e861e) — Source: Beyond Air
- 2026-04-20 12:00 EST — [Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026](https://biopharmsignal.com/news/XAIR/beyond-cancer-reports-updated-survival-and-safety-data-from-phase-1-uno-trial-pr-2ccd5ce5) — Source: Beyond Air
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)